-
Although current guidelines recommend delaying neuroprognostication during therapeutic hypothermia following resuscitation from cardiac arrest, this review of 55 consecutive patients so managed found that a "poor prognosis" designation was arrived at during the hypothermia period in most of them, including six patients who were eventually discharged with a favorable neurologic outlook.
-
Timely recognition and treatment of myocardial infarction (MI) are crucial if we are to achieve optimal outcomes for our patients. Silent ischemia, or the absence of classical symptoms of ischemia, may delay the diagnosis.
-
Infection is the second leading cause of death in hemodialysis patients, with mortality rates ranging from 12-36% in this vulnerable population.
-
Two ICU patients experienced respiratory arrest while receiving polymyxin. Given the recent resurgence of use of this antibiotic and its close relative colistin to treat gram-negative infections resistant to newer agents, clinicians should be aware of this infrequent but long-known and potentially fatal adverse effect.
-
-
More than half of patients undergoing non-cardiac surgery and polysomnography had obstructive sleep apnea, which was associated with an increased risk of perioperative complications, including hypoxemia, ICU transfer, and prolonged length of stay.
-
The choice of if and when to employ pharmacotherapy in the management of Alzheimer's disease (AD) is not an easy one.
-
The FDA has approved an extended-release, once-daily, dipeptidyl-4 (DPP-4) inhibitor in combination with metformin for adults with type 2 diabetes. Janumet XR combines sitagliptin and metformin. The new combination is the second such product joining Kombiglyze XR, which combines saxagliptin and metformin. Janumet XR is marketed by Merck & Co., Inc.
-
Rapid influenza diagnostic tests have modest sensitivity and high specificity.
-
A retrospective survey of 744 Dutch and Belgian travelers who had ventured to 2500 m (8200 feet) or higher revealed that 25% developed acute mountain sickness. Only half of this group had followed pre-travel advice regarding altitude sickness, and few took preventive acetazolamide.
